Indian pharmaceutical companies are eyeing $ 145 billion US cancer drug market to gain large share in the market. This market is growing at 11 per cent compound rate every year. For the past few months, many Indian pharmaceutical companies have received approval from the American medicine regulator (USFDA) for cancer generic medicines, which has steadily increased in the US market.
In 2024, the price of the US cancer drug market was estimated at $ 145.52 billion and by 2034 it is estimated to be $ 416.93 billion. In this context, between 2025 and 2034, its annual 11.1 percent is increasing at the rate of compound rate.
Experts believe that the approval of Cipla, Biocon Biological and Zayadas LifeSians indicates the growing abilities of Indian companies in the complex sector of cancer treatment and their growing presence in the attractive American market. Indian companies have been focusing on complex generics for some time, saving them from the pressure of pricing in the generic sector in the US.
Ikra's vice-president and group co-head Kinjal Shah said, “The FDA process has become normal since the global epidemic and now Indian companies are focusing on complex molecules such as cancer drugs, as the basic generic has reached its highest level.”
Biocon Biological on April 10 announced the FDA approval for the biosimiller Jobeven (Bewakijumab-NUGD) of Avastin. It is used in the treatment of various cancers such as colorectal, lungs and glioblastoma. This is Biocon's seventh biosimiler approved in the US, with its portfolio of its cancer drugs. The company also sells biosimillers such as Ogivari and Phulfila in the US, Europe and Canada.
Cipla obtained approval from the American drug regulator for his AB-Remed-Genetic version of Abrose. Its use is used in breast cancer, non-small cell lungs and pancreatic cancer and this drug of Cipla can come in the US in the first half of 2025-26. In March, Zayadas also approved Erleda's generic drug used to treat metastatic caustation-sensitive prostate cancer.
First Published – April 18, 2025 | 11:13 PM IST
